Sysmex (OTCMKTS:SSMXY) Releases FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.382-0.382 for the period, compared to the consensus estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Sysmex Stock Up 0.6%

Sysmex stock opened at $10.30 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The business’s 50-day simple moving average is $9.34 and its two-hundred day simple moving average is $9.06. Sysmex has a fifty-two week low of $8.01 and a fifty-two week high of $14.24. The company has a market cap of $6.48 billion, a PE ratio of 27.11 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Equities analysts anticipate that Sysmex will post 0.42 EPS for the current year.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.